Details

Autor(en) / Beteiligte

• Ejiri, Kentaro
• Miyoshi, Toru
• Kihara, Hajime
• Hata, Yoshiki
• Nagano, Toshihiko
• Takaishi, Atsushi
• Toda, Hironobu
• Namba, Seiji
• Nakamura, Yoichi
• Akagi, Satoshi
• Sakuragi, Satoru
• Minagawa, Taro
• Kawai, Yusuke
• Nishii, Nobuhiro
• Fuke, Soichiro
• Yoshikawa, Masaki
• Nakamura, Kazufumi
• Ito, Hiroshi
• Sato, Tetsuya
• Sugiyama, Hiroyasu
• Imai, Michio
• Gotoh, Naoki
• Segawa, Tomonori
• Noda, Toshiyuki
• Koshiji, Masatoshi

Titel

Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure

Ist Teil von

• Scientific reports, 2022-09, Vol.12 (1), p.15449-15449, Article 15449

Ort / Verlag

London: Nature Publishing Group

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Abstract Sodium-glucose cotransporter 2 inhibitors could reduce cardiovascular events in patients with heart failure irrespective of diabetes status. In this prespecified sub-analysis of randomised-controlled trial, we investigated the efficacy of luseogliflozin (2.5 mg daily), a sodium–glucose cotransporter 2 inhibitor, with that of voglibose (0.6 mg daily), an alpha-glucosidase inhibitor, on high-risk lipid profile and inflammatory markers in patients with type-2 diabetes and heart failure. Among the 157 patients studied, there were no significant differences in the mean malondialdehyde LDL or small-dense LDL cholesterol levels between the luseogliflozin and voglibose groups (percent change: 0.2% vs. − 0.6%, p = 0.93; − 1.7% vs. − 8.6%, p = 0.21) after 12 weeks in comparison to levels at the baseline. No significant difference was observed between the two groups in the adiponectin and high-sensitivity C-reactive protein levels after 12 weeks compared to the baseline levels (percent change, − 1.6% vs. − 4.0% and 22.5% vs. 10.0%; p = 0.52 and p = 0.55, respectively). In conclusion, in patients with type-2 diabetes and heart failure, compared to voglibose, luseogliflozin did not significantly improve the high-risk lipoprotein profile including malondialdehyde LDL and small-dense LDL cholesterol or the levels of inflammatory markers, including adiponectin and high-sensitivity C-reactive protein. Trial registration: Trial number: UMIN-CTR, UMIN000018395; Registered 23 July 2015; URL: https://www.umin.ac.jp/ctr/index.htm .